$0.621
+0.016 (+2.53%)At close
CELZ Profitability and Margins
Evaluating the bottom line, Creative Medical Technology Holdings Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -78.03%, provide a clear picture of how effectively CELZ converts its operational activities into shareholder value.
CELZ Comparative Benchmarking
In the context of the broader market, CELZ competes directly with industry leaders such as WOK and TRIB. With a market capitalization of $4.71M, it holds a significant position in the sector. When comparing efficiency, CELZ's gross margin of N/A stands against WOK's 19.14% and TRIB's 35.43%. Such benchmarking helps identify whether Creative Medical Technology Holdings Inc is trading at a premium or discount relative to its financial performance.
Creative Medical Technology Holdings Inc Financial Performance
Creative Medical has shown inconsistent revenue, with total revenue of $3,000 in Q4 2024 and losses in subsequent quarters. The gross margin remains negative, indicating challenges in cost management.
Financials
Related articles
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.